Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (QNTM)

Quantum BioPharma (NASDAQQNTM) announced the successful completion of its Phase 1 clinical trial evaluating Lucid-21-302 (“Lucid-MS”), a first-in-class neuroprotective compound for multiple sclerosis. A final safety review committee meeting confirmed that Lucid-MS was well-tolerated with no serious adverse events. The drug, designed to stabilize the myelin sheath and protect against demyelination, showed promising safety results, paving the way for a Phase 2 trial in MS patients. Company executives emphasized the milestone as a key step toward drug approval and commercialization.

Safety Review Committee Found No Safety Concerns Following Milestone Trial

TORONTO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQQNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce that after receiving approval from the Board of Directors, the Company has purchased an additional USD $1,000,000 worth of Bitcoin (“BTC”) and other cryptocurrencies as part of its strategic efforts. This brings the total amount of BTC and other cryptocurrencies purchased to USD $2,000,000. As previously announced, the company will continue to allow for future financing and other transactions to be carried out in cryptocurrency.

Quantum BioPharma Ltd. Dual Lists on Upstream's Global Securities Trading App

Trading to become available January 14th under 'QNTM'

Quantum BioPharma (NASDAQQNTM) has retained MZHCI, an MZ Group company, to lead its investor relations and financial communications efforts. The initiative aims to enhance the company’s visibility within the investment community, emphasizing its portfolio focused on brain disorders and alcohol health. MZ will highlight Quantum BioPharma’s products, including unbuzzd and rekvry, which address excessive alcohol use, and its research into demyelinating diseases such as multiple sclerosis. Chris Tyson, executive vice president at MZ North America, noted the significant market potential for these innovations.

TORONTO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQQNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced it has retained the services of MZHCI, LLC, an MZ Group Company (“MZ”), to lead a comprehensive strategic investor relations and financial communications program across all key markets.

Quantum BioPharma (NASDAQQNTM) has retained Enterprise Canada Inc. and Empire Market Ventures, LLC to lead its public relations and investor awareness efforts. Enterprise, engaged indefinitely, will develop the company’s media strategy, while Empire, engaged for three months starting Feb. 7, 2025, will focus on investor marketing and outreach. The company highlighted progress on its key products, including unbuzzd, a rapid alcohol detoxification beverage set for Q1 2025 availability, rekvry , an alcohol misuse treatment, and LUCID-21-302, a potential multiple sclerosis treatment moving toward Phase 2 trials.

TORONTO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQQNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced it has retained the services of Enterprise Canada Inc. (“Enterprise”) and Empire Market Ventures, LLC (“Empire”) (together, the “Agencies”) to lead its comprehensive public relations and investor awareness programs, respectively, across all key markets.

Quantum BioPharma (NASDAQQNTM) announced that its licensee, Celly Nutrition Corp., has engaged a leading New York investment bank to raise up to $10 million and explore an initial public offering on a major U.S. exchange. Quantum BioPharma holds a 25.71% stake in Celly Nutrition and receives a 7% royalty on sales of its product, unbuzzd, until payments total $250 million, after which royalties drop to 3% in perpetuity. Celly Nutrition signed a Letter of Engagement on Feb. 4, 2025, for advisory services related to a potential uplisting, reverse merger, or IPO. CEO John Duffy emphasized the capital raise will support marketing and distribution expansion for unbuzzd, while Board Co-Chair Gerry David highlighted strong investor interest in the brand.

TORONTO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- BioPharma Ltd. (NASDAQQNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that its licensee Celly Nutrition Corporation, the company behind unbuzzdTM – the scientifically-proven and game-changing beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms –announced that it has engaged a leading New York Investment Bank to raise up to $10 million USD in capital and explore an initial public offering on a major US public exchange, subject to requisite regulatory approval.

Quantum BioPharma (NASDAQQNTM) announced the successful completion of a clinical trial demonstrating that its dietary supplement, unbuzzd, significantly accelerates alcohol metabolism and reduces symptoms of intoxication and hangovers. The double-blind, placebo-controlled study showed that unbuzzd lowered blood alcohol concentration by over 40% faster within 30 minutes compared to placebo, while improving alertness and stabilizing heart rate and blood pressure. Participants also reported reduced mental fatigue and hangover symptoms without adverse side effects. Quantum BioPharma CEO Zeeshan Saeed highlighted unbuzzd as a breakthrough in promoting safe and responsible alcohol consumption.

Trial Confirms unbuzzd™ Dramatically Accelerates Alcohol Metabolism, Speeds the Reduction of Blood Alcohol Concentration, and Reduces Symptoms of Intoxication, Impairment and Hangover

Quantum BioPharma (NASDAQQNTM) (CSE: QNTM) is a biopharmaceutical company committed to developing innovative solutions to address neurodegenerative and metabolic disorders, as well as alcohol misuse. The company’s portfolio includes groundbreaking therapeutic candidates such as Lucid-MS, a patented compound targeting multiple sclerosis, and consumer-focused products like unbuzzd(TM), a novel alcohol detoxification beverage. Through strategic investments and a focused R&D model, Quantum BioPharma seeks to deliver meaningful health improvements while maximizing shareholder value.

Awards in favour of Quantum BioPharma Total Approximately $3 Million

TORONTO, ON / ACCESSWIRE / December 20, 2024 / Quantum BioPharma Ltd. (NASDAQQNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), is pleased to announce that after receiving approval from the Board of Directors, the Company has purchased USD $1,000,000 Bitcoin (BTC) and other cryptocurrencies as part of its strategic efforts. As well, going forward the Company will allow for future financing and other transactions to be carried out in cryptocurrency.

TORONTO, ON / ACCESSWIRE / December 10, 2024 / Quantum BioPharma Ltd. (NASDAQQNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces through its subsidiary, HUGE Biopharma Australia Pty Ltd., that the safety review committee recommends commencing dosing of the second cohort in its trial entitled "A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants." The safety review committee made this recommendation after reviewing safety and pharmacokinetic data from participants in the first cohort.

TORONTO, ON / ACCESSWIRE / November 25, 2024 / Quantum BioPharma Ltd. (NASDAQQNTM)(CSE:QNTM)(FRA:0K91) (the "Company") formerly named FSD Pharma Inc. (Nasdaq:HUGE)(CSE:HUGE) is pleased to follow up on recent events concerning the complaint filed by the Company in the United States courts, that alleges that CIBC World Markets, RBC Dominion Securities and others (the "Defendants") engaged in market manipulation in the share price of the Company. The Company, as well as its shareholders, have suffered financial and emotional losses resulting from this alleged manipulation. We are determined to right this wrong by the Defendants and reverse the Company losses and claim punitive damages to the extent determined by the courts. As a result, prominent legal teams have been assembled to pursue the recovery of all losses and damages impacting our Company. The law firms have agreed to be compensated without cost to the Company but solely on a contingency basis, meaning that the Company will not be billed for legal costs in this matter. The Company itself is seeking damages of more than US$700M we believe it has suffered. The shareholders can find updated information about the case on the Quantum vs Banks page of our website which will be updated periodically.

TORONTO, ON / ACCESSWIRE / October 29, 2024 / Quantum BioPharma Ltd. (NASDAQQNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces through its subsidiary, HUGE Biopharma Australia Pty Ltd., that sentinel dosing has started for its trial entitled "A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants."

To assist enquiries the copy of the complaint can be viewed by clicking the following link: Quantum Bio Pharma Complaint

Christian Attar Law Firm and Freedman Normand Friedland LLP, in conjunction with forensic investigators, have uncovered evidence of a potential multi-year market manipulation scheme that has caused substantial damages to the Company and its shareholders

As the health and wellness sector gains momentum, consumers are increasingly seeking products that can aid recovery from the effects of alcohol. Quantum BioPharma Ltd. (NASDAQQNTM) (CSE: QNTM), a company focused on developing innovative health solutions, is well-positioned to meet this demand with its groundbreaking product designed to support the body in metabolizing alcohol.

TORONTO, ON / ACCESSWIRE / October 7, 2024 / Quantum BioPharma Ltd. (NASDAQQNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma"), provides an update by way of a news release issued by Celly Nutrition Corp. ("Celly Nu"), and its launching of unbuzzd™, an innovative beverage product that is scientifically formulated from a proprietary blend of vitamins, minerals and botanical extracts designed to support the body's natural processes for metabolizing alcohol and promoting alertness.

TORONTO, ON / ACCESSWIRE / September 27, 2024 / Quantum BioPharma Ltd. (formerly, FSD Pharma Inc.) (NASDAQQNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce the following corporate updates.

TORONTO, ON / ACCESSWIRE / September 25, 2024 / Quantum BioPharma Ltd. (formerly, FSD Pharma Inc.) (NASDAQQNTM) (CSE:QNTM) (FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that Jason Sawyer, Head of Finance and Mergers and Acquisitions, will present at the ArcStone-Kingswood Growth Summit held on September 26, 2024, in Toronto, ON. The event will feature over 30 public and private companies and 47 sponsors from around the world.